ArticleBMC cancer2025
Clinical analysis of pulmonary mucosa-associated lymphoid tissue lymphoma coexisting with lung cancer.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Five Cases of Primary Pulmonary Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma With Atypical Image Findings and Literature Review: A Case Series.Respirology case reports · 2026Article
- Pulmonary Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue (PMZL-MALT) Diagnosed by Radial Probe Endobronchial Ultrasound-Guided Biopsy: A Case Report.Case reports in pulmonology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPrimary pulmonary Mucosa-associated lymphoid tissue (MALT) lymphoma is a sporadic disease with a favorable prognosis. Particularly, pulmonary MALT lymphoma coexisting with lung cancer is not only rare but also prone to misdiagnosis. The clinical characteristics and prognostic factors of this co-occurrence, however, remain poorly understood.
methodsWe retrospectively analyzed the clinical, imaging, genetic mutations and pathological data among adult patients with pulmonary MALT lymphoma coexisting with lung cancer who were confirmed by pathological examinations after operation at Shanghai Pulmonary Hospital between 1st January 2013 and 31st May 2024.
resultsAfter exclusions, a total of 14 patients were included in the study, of which eleven patients were women and only 3 were men, with a median age of 57 [IQR: 53-67] years. Pulmonary MALT lymphoma presented a median diameter of 14 mm (IQR: 6-23). Nodule was the most frequent CT feature and existing pattern of pulmonary lesions (n = 8). The lung cancer was with a median diameter of 10.7 [IQR:6,20] mm, with nodules as the predominant CT feature (n = 12). Six patients manifested dual primary malignancies within the same lung lobe, termed collision tumors, whereas the remaining eight had lesions in different lobes. Five cases exhibited EGFR mutant, and one case showed no mutation. 13 patients were pathological confirmed with lung adenocarcinoma and one with microcarcinoma. Postoperatively, all-cause mortality rate was low, indicating a positive prognosis. One patient died 41 months after surgery due to a pulmonary infection, while the remaining 13 patients were in good condition with an average follow-up of 37.92 months.
conclusionsIn patients with pulmonary lesions, particularly multiple lesions, comprehensive preoperative evaluation is crucial to prevent misdiagnosis or missed diagnoses. Besides, surgical resection is desirable when both lung cancer and MALT are at an early stage and can be resected with minimally invasive surgery (minimally lung resection).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.